Sera Prognostics Q4 revenue falls, net loss narrows

Sera Prognostics

18/03/2026 20:16

Overview

Pregnancy diagnostics company's Q4 revenue fell yr/yr

Net loss for Q4 narrowed compared to prior-year period

Outlook

Company expects cash position to fund operations through significant milestones into 2028

Result Drivers

COMMERCIAL INVESTMENT - Co said it continued targeted commercial activities and strategic headcount additions in Q4 while building market awareness in preparation for PRIME study publication

R&D SPENDING - Research and development expenses were stable in Q4, with full-year decline attributed to lower clinical study costs after completion of the PRIME study

Company press release: ID:nPnbhhS0Sa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Miss
$10,000
$30,000 (2 Analysts)
Q4 Net Income
-$7.9 mln
Q4 Basic EPS
-$0.16
Q4 Income from Operations
-$8.95 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the business support services peer group is "buy."

Wall Street's median 12-month price target for Sera Prognostics Inc is $5.00, about 148.8% above its March 17 closing price of $2.01

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)